Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Pavlakis

Showing results (281-290 of 294) with videos related to

Pageof 30
Sort By:
Journal of Virology|July 8, 2011
Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimenNicola Winstone, Aaron J Wilson, Gavin Morrow, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 30, 2013
DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challengeVainav Patel, Rashmi Jalah, Viraj Kulkarni, et al.
Microorganisms|December 2, 2020
Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical StudyEvangelos Terpos, Marianna Politou, Theodoros N Sergentanis, et al.
Journal of Virology|April 10, 2015
Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein BoostSandrine L Hulot, Bette Korber, Elena E Giorgi, et al.
Journal of Virology|May 29, 2015
Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman PrimatesXiaoying Shen, Ryan Duffy, Robert Howington, et al.
Clinical Immunology (Orlando, Fla.)|June 8, 2014
Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responsesDiego A Vargas-Inchaustegui, Iskra Tuero, Venkatramanan Mohanram, et al.
Journal of Virology|May 26, 2018
Control of Heterologous Simian Immunodeficiency Virus SIV<sub>smE660</sub> Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in MacaquesShakti Singh, Eric G Ramírez-Salazar, Rami Doueiri, et al.
AIDS (London, England)|December 5, 2023
The immunogenicity of an HIV-1 Gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapyJeffrey M Jacobson, Barbara K Felber, Huichao Chen, et al.
Nature Medicine|May 23, 2018
HIV vaccine candidate activation of hypoxia and the inflammasome in CD14<sup>+</sup> monocytes is associated with a decreased risk of SIV<sub>mac251</sub> acquisitionMonica Vaccari, Slim Fourati, Shari N Gordon, et al.
Plos Pathogens|July 6, 2021
Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacyFredrik Barrenäs, Scott G Hansen, Lynn Law, et al.
Pageof 30

Showing results (281-290 of 294) with videos related to

Sort By:
Pageof 30
Journal of Virology|July 8, 2011
Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimenNicola Winstone, Aaron J Wilson, Gavin Morrow, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 30, 2013
DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challengeVainav Patel, Rashmi Jalah, Viraj Kulkarni, et al.
Microorganisms|December 2, 2020
Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical StudyEvangelos Terpos, Marianna Politou, Theodoros N Sergentanis, et al.
Journal of Virology|April 10, 2015
Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein BoostSandrine L Hulot, Bette Korber, Elena E Giorgi, et al.
Journal of Virology|May 29, 2015
Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman PrimatesXiaoying Shen, Ryan Duffy, Robert Howington, et al.
Clinical Immunology (Orlando, Fla.)|June 8, 2014
Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responsesDiego A Vargas-Inchaustegui, Iskra Tuero, Venkatramanan Mohanram, et al.
Journal of Virology|May 26, 2018
Control of Heterologous Simian Immunodeficiency Virus SIV<sub>smE660</sub> Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in MacaquesShakti Singh, Eric G Ramírez-Salazar, Rami Doueiri, et al.
AIDS (London, England)|December 5, 2023
The immunogenicity of an HIV-1 Gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapyJeffrey M Jacobson, Barbara K Felber, Huichao Chen, et al.
Nature Medicine|May 23, 2018
HIV vaccine candidate activation of hypoxia and the inflammasome in CD14<sup>+</sup> monocytes is associated with a decreased risk of SIV<sub>mac251</sub> acquisitionMonica Vaccari, Slim Fourati, Shari N Gordon, et al.
Plos Pathogens|July 6, 2021
Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacyFredrik Barrenäs, Scott G Hansen, Lynn Law, et al.
Pageof 30